SCHEMBL7130474

SCHEMBL7130474

CC(C)(C)OC(=O)Nc1cc(Cl)cc(N(S)C(N)=O)c1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 3/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA9 Q16790 2/20 0.34
MAP4K4 O95819 1/20 0.34
SLC13A3 Q8WWT9 1/20 0.34
SIRT2 Q8IXJ6 1/20 0.34
SIRT1 Q96EB6 1/20 0.34
CDK1 P06493 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
EGFR P00533 1/20 0.33
SRC P12931 1/20 0.33
CYP17A1 P05093 1/20 0.33
ATR Q13535 1/20 0.33
CA2 P00918 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6811311 0.82 SLC13A3 (0.40) MAPKAPK2CA12CA1CA9SLC13A3
SCHEMBL5879121 0.80 L3MBTL1 (0.47) CA12CA1CA9SLC13A3L3MBTL1
SCHEMBL3786493 0.80 L3MBTL1 (0.44) CA12CA1CA9SLC13A3SIRT2
SCHEMBL7130465 0.77 MAPKAPK2 (0.41) MAPKAPK2CA12CA1CA9MAP4K4
SCHEMBL6810856 0.76 MAPKAPK2 (0.42) MAPKAPK2CA12CA1CA9MAP4K4
SCHEMBL31254121 0.76 MAPKAPK2 (0.42) MAPKAPK2CA12CA1CA9MAP4K4
SCHEMBL31093899 0.75 CA12 (0.43) CA12CA1CA9SLC13A3SIRT2
SCHEMBL22081738 0.75 CA12 (0.43) CA12CA1CA9SLC13A3SIRT2
SCHEMBL22032877 0.74 CA12 (0.39) MAPKAPK2CA12CA1CA9SLC13A3
SCHEMBL22081737 0.74 LCK (0.41) CA12CA1CA9SLC13A3SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 MAPKAPK2 3499/4885CA12 230/4885CA1 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.